Immunic Updates Corporate Strategy, Highlights Vidofludimus PlansTip Ranks·Jul 15 at 03:05 AMIMUX-4.56%
Immunic publishes investor presentation outlining vidofludimus calcium Phase 3 program in multiple sclerosisPUBT·Jul 14 at 07:19 AMIMUX-4.56%
Immunic to Participate in Investor Conferences in July | IMUX Stock NewsStockTitan·Jul 8 at 09:30 PMIMUX-4.56%RILY-2.72%
Immunic names CEO Erik Lundgren to board after Tamar Howson retirement resignationPUBT·Jul 6 at 03:23 PMIMUX-4.56%
Immunic holds annual shareholder meeting, backs 6 million-share increase to equity planPUBT·Jun 29 at 03:06 PMIMUX-4.56%
Immunic to Participate in Investor, Industry and Scientific Conferences in JuneUnusual Whales·Jun 10 at 05:33 AMIMUX-4.56%
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | IMUX Stock NewsStockTitan·May 27 at 09:30 PMIMUX-4.56%IXJ+2.12%
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer | IMUX Stock NewsStockTitan·May 26 at 09:30 PMIMUX-4.56%FBT+1.53%
